每经AI快讯，南京医药（SH 600713，收盘价：5.05元）10月30日晚间发布公告称，公司第十届第四次 董事会会议于2025年10月29日在公司14楼1403会议室召开。会议审议了《关于增补第十届董事会非独立 董事的议案》等文件。 每经头条（nbdtoutiao）——多地出现"负电价"，既然卖电"不挣钱"，为何电厂不愿停机？ 2024年1至12月份，南京医药的营业收入构成为：批发占比94.72%，零售占比4.53%，电商占比0.48%， 其他业务占比0.24%，第三方物流占比0.03%。 （记者 贾运可） 截至发稿，南京医药市值为66亿元。 ...

| 证券简称：南京医药 | 编号：ls2025-135 | | --- | --- | | 证券代码：600713 | | 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 关于修订公司章程相关条款并取消监事会、变更公司全称及 注册资本的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 拟变更后的公司全称：南京医药股份有限公司（以下简称"公司"）拟 更名为"南京医药集团股份有限公司"（暂定名，最终以在市场监督管理部门备 案后的名称为准），英文名称拟变更为"Nanjing Pharmaceutical Group Company Limited"。证券简称、证券代码均保持不变。 公司拟取消监事会，由董事会审计与风险控制委员会行使《公司法》规 定的监事会职权，《南京医药股份有限公司监事会议事规则》相应废止。 公司拟修订注册资本为 1,308,929,289 股。 公司拟根据新《公司法》、《上市公司章程指引》等法律法规的规定， 对《公司章程》及其附件《南京医药股份有限公司股东大会议事规则》《南京医 ...

南京医药股份有限公司章程修正案 | 序号 | 修订前 | 修订后 | | --- | --- | --- | | | 原第一条 为维护公司、股东和债权人的合法 | 现第一条 为维护公司、股东、职工和债 | | | | 权人的合法权益，规范公司的组织和行 | | | 权益,规范公司的组织和行为,根据《中华人民 | 为，根据《中华人民共和国公司法》（以 | | 1 | 共和国公司法》（以下简称《公司法》）、 | 下简称《公司法》）、《中华人民共和国 | | | 《中华人民共和国证券法》（以下简称《证 | 证券法》（以下简称《证券法》）和其他 | | | 券法》）和其他有关规定，制订本章程。 | 有关规定，制定本章程。 | | | | 现第四条 公司注册名称: 南京医药集团 | | | 原第四条 公司注册名称:南京医药股份有限 | 股份有限公司 | | 2 | 公司 | 公司简称：南京医药 | | | 公司英文名称:Nanjing Pharmaceutical Co., Ltd. | | | | | 公 司英 文 名称 : Nanjing Pharmaceutical | | | | Group Company L ...

| 公告编号：ls2025-136 | | --- | | 证券代码：600713 | | 证券简称：南京医药 | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2025年第二次临时股东大会 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 关于召开2025年第二次临时股东大会的通知 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票 相结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2025 年 11 月 19 日 14 点 00 分 召开地点：南京市雨花台区安德门大街 55 号 2 幢 8 层会议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 11 月 19 日 至2025 年 11 月 19 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易 ...

| | | 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 第十届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本议案在提交董事会审议前，已提交公司第十届董事会审计与风险控制委员 会 2025 年第三次会议审议通过（同意 4 票，反对、弃权均为 0 票），委员一致 同意将本议案提交董事会审议。 2、审议通过关于修订《南京医药股份有限公司章程》相关条款并取消监事 会、变更公司全称及注册资本的议案； 同意公司根据新《公司法》、《关于新<公司法>配套制度规则实施相关过 渡期安排》等相关制度规定及监管要求，结合公司实际情况，取消监事会，由董 事会审计与风险控制委员会行使《公司法》规定的监事会职权，《南京医药股份 有限公司监事会议事规则》相应废止，同时对《南京医药股份有限公司章程》及 其附件《南京医药股份有限公司股东大会议事规则》《南京医药股份有限公司董 事会议事规则》进行修订。 重要内容提示： 一、董事会会议召开情况 南京医药股份有限公司（以下简称"公司"）第十届董事会第四次会议于 202 ...

Financial Performance - The company's operating revenue for the third quarter was CNY 13,167,730,186.85, a decrease of 3.93% compared to the same period last year[5] - The total profit for the quarter was CNY 181,692,169.91, down 18.04% year-on-year[5] - The net profit attributable to shareholders was CNY 110,694,512.43, reflecting a decline of 15.22% compared to the previous year[5] - The basic earnings per share decreased by 10.00% to CNY 0.09, while diluted earnings per share fell by 20.00% to CNY 0.08[5] - Total operating revenue for the first three quarters of 2025 reached ¥41.14 billion, a slight increase of 0.48% compared to ¥40.94 billion in the same period of 2024[38] - Net profit for the first three quarters of 2025 was ¥529.76 million, down 6.04% from ¥563.81 million in the previous year[39] - The total comprehensive income for the first three quarters of 2025 was ¥527.35 million, down from ¥591.96 million in 2024, reflecting a decline of 10.87%[39] - The net profit for the first three quarters of 2025 was CNY 336,047,245.31, down 8.0% from CNY 365,157,231.84 in the first three quarters of 2024[45] Assets and Liabilities - Total assets increased by 10.99% to CNY 34,045,054,183.45 compared to the end of the previous year[5] - As of September 30, 2025, the company's total assets amounted to RMB 34,045,054,183.45, an increase from RMB 30,673,626,932.52 as of December 31, 2024[34] - Current assets totaled RMB 31,003,426,359.15, compared to RMB 27,807,861,740.60 at the end of 2024, reflecting a growth of approximately 11.5%[35] - The total liabilities and shareholders' equity reached ¥34.05 billion, an increase of 10.00% from ¥30.67 billion in the previous year[38] - The total liabilities increased to CNY 13,892,435,691.26 as of September 30, 2025, compared to CNY 12,444,743,701.74 at the end of 2024[43] Cash Flow - Cash flow from operating activities showed a significant decline, primarily due to reduced sales collections[8] - The net cash flow from operating activities for the first three quarters of 2025 was -¥4.98 billion, worsening from -¥2.89 billion in the same period of 2024[41] - The company's cash flow from operating activities showed a net outflow of CNY 1,705,552,524.18 for the first three quarters of 2025, compared to a net outflow of CNY 1,101,127,686.26 in the same period of 2024[46] - The net cash flow from investing activities was -$2.08 billion, compared to -$1.53 billion in the previous period[47] - The net cash flow from financing activities was $2.45 billion, up from $1.62 billion in the prior period[47] - The company experienced a net decrease in cash and cash equivalents of -$1.34 billion, compared to -$1.01 billion in the previous period[47] Shareholder Information - The company reported a total of 51,638 common shareholders at the end of the reporting period[10] - The largest shareholder, Nanjing New Industry Investment Group Co., Ltd., holds 44.17% of the shares[10] - The company repurchased 17,999,852 shares, accounting for 1.38% of the total share capital, with a total expenditure of RMB 88,922,100[17] Investments and Financing - The company issued 10,814,910 convertible bonds with a total fundraising amount of RMB 1,081,491,000, net amount after expenses being RMB 1,069,040,922.31[13] - The company issued short-term financing bonds totaling RMB 15 billion to supplement working capital and repay bank loans[19] - The company approved a borrowing limit of up to RMB 4 billion from its controlling shareholder for daily operational funding[24] - The company signed a strategic investment agreement with Guangzhou Baiyunshan Pharmaceutical Group, where Baiyunshan's subsidiary plans to acquire 144,557,431 shares from Alliance Healthcare, representing 11.04% of the company's total shares[27] Research and Development - Research and development expenses decreased to ¥25.90 million in 2025 from ¥30.54 million in 2024, indicating a reduction of 15.36%[38] - The company reported a decrease in research and development expenses to CNY 7,576,143.84 in the first three quarters of 2025, down from CNY 8,818,792.19 in the same period of 2024[44] Other Information - The company completed the purchase of its headquarters building for a total price of RMB 326,736,120.00[29] - The company held a half-year performance briefing on September 18, 2025, to address investor concerns and provide updates on its financial performance[32] - The company appointed several new vice presidents, aligning their terms with the current board's tenure[33] - The company will not apply new accounting standards starting from 2025[48]

南京医药股份有限公司ESG工作细则 第一章 总则 第一条 为建立健全南京医药股份有限公司（以下简称"公司"）环 境、社会及公司治理（Environmental, Social and Governance，以下简称 "ESG"）管理体系，提升公司可持续发展能力，推动ESG理念与公司战 略和运营的深度融合，实现ESG工作的规范化、体系化管理，根据国家 相关法律法规、监管要求及公司章程，结合公司实际，特制定本工作细 则。 第二章 ESG管理架构 第二条本细则适用于公司及其全资或控股子公司。 第三条 公司构建多层级联动的ESG管理架构，明确董事会、管理 层及各部门、分子公司在ESG管理中的职责权限，建立决策、执行、 监督协同配合的高效运行机制，确保ESG管理体系的有效运转，推动 公司可持续发展战略目标的实现。 第四条 公司董事会战略决策与投融资管理委员会作为董事会授 权的ESG事务专责机构，在董事会领导下开展工作，主要履行以下职 责： （五）通过审议公司定期报告，对质量管理、安全生产等方面的 ESG风险和机遇加强识别与管理； （六）审阅公司年度ESG报告及重大ESG信息披露事项，并提交 董事会审议； （一）了解ES ...

Market Overview - The pharmaceutical commercial sector increased by 0.32% compared to the previous trading day, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3996.94, up 1.18%, while the Shenzhen Component Index closed at 13489.4, up 1.51% [1] Stock Performance - Jianfa Zhixin (301584) closed at 39.29, up 10.18% with a trading volume of 315,400 shares and a transaction value of 1.142 billion [1] - Run Da Medical (603108) closed at 15.30, up 3.66% with a trading volume of 180,900 shares and a transaction value of 274 million [1] - Other notable performers include Huaren Health (301408) up 2.28%, and Saili Medical (603716) up 1.98% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 6.1445 million from institutional investors, while retail investors saw a net inflow of 56.1279 million [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors increased their positions [2] Individual Stock Capital Flow - Run Da Medical saw a significant net outflow of 49.9539 million from institutional investors, indicating a bearish sentiment [3] - Conversely, Jiuzhoutong (866000) had a net inflow of 16.7641 million from institutional investors, suggesting positive interest [3] - Other stocks like Nanjing Medical (600713) and Huaren Health (301408) also showed varying degrees of net inflows and outflows from different investor categories [3]

Core Insights - The pharmaceutical commercial sector experienced a decline of 1.0% on October 24, with Jianfa Zhixin leading the drop [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Market Performance - The following companies showed varied performance in the pharmaceutical commercial sector: - Huaren Health (301408) closed at 13.17, up 0.46% with a trading volume of 44,500 shares and a turnover of 58.44 million yuan [1] - Runda Medical (603108) closed at 14.76, up 0.20% with a trading volume of 64,400 shares and a turnover of 95.39 million yuan [1] - Jianfa Zhixin (301584) led the decline, closing at 35.66, down 4.14% with a trading volume of 341,300 shares and a turnover of 1.289 billion yuan [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 259 million yuan from institutional investors, while retail investors contributed a net inflow of 248 million yuan [2] - The following companies had notable capital flows: - Shanghai Pharmaceutical (601607) had a net inflow of 6.9169 million yuan from institutional investors [3] - Baiyang Pharmaceutical (301015) experienced a net inflow of 6.5687 million yuan from institutional investors [3] - Runda Medical (603108) had a net inflow of 3.8868 million yuan from retail investors [3]

证券日报网讯 10月23日晚间，南京医药发布公告称，截至2025年10月22日，公司完成回购，公司已通 过集中竞价交易方式累计回购公司股份1，799.9852万股，占公司2025年10月22日总股本130，893.0265 万股的1.38%。 （文章来源：证券日报） ...